Cytori Therapeutics Inc (CYTX) Issues Quarterly Earnings Results
Cytori Therapeutics Inc (NASDAQ:CYTX) posted its quarterly earnings results on Thursday. The biotechnology company reported ($0.18) EPS for the quarter, missing the consensus estimate of ($0.16) by $0.02, Morningstar.com reports. The firm had revenue of $0.90 million during the quarter, compared to analyst estimates of $2.23 million. Cytori Therapeutics had a negative net margin of 491.71% and a negative return on equity of 177.92%. The company’s revenue was down 18.2% on a year-over-year basis. During the same period last year, the company earned ($0.43) EPS.
Cytori Therapeutics (CYTX) opened at 0.3497 on Friday. Cytori Therapeutics has a one year low of $0.32 and a one year high of $2.29. The stock has a 50 day moving average price of $0.82 and a 200-day moving average price of $1.22. The firm’s market capitalization is $11.36 million.
Several equities analysts have commented on the company. B. Riley reaffirmed a “neutral” rating on shares of Cytori Therapeutics in a report on Sunday, July 30th. Maxim Group set a $10.00 price target on Cytori Therapeutics and gave the company a “buy” rating in a report on Saturday, May 13th. Zacks Investment Research cut Cytori Therapeutics from a “buy” rating to a “hold” rating in a report on Wednesday, July 12th. Finally, ValuEngine cut Cytori Therapeutics from a “sell” rating to a “strong sell” rating in a report on Tuesday, August 1st.
A hedge fund recently raised its stake in Cytori Therapeutics stock. Perkins Capital Management Inc. raised its position in shares of Cytori Therapeutics Inc (NASDAQ:CYTX) by 10.2% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 439,679 shares of the biotechnology company’s stock after buying an additional 40,839 shares during the period. Perkins Capital Management Inc. owned about 1.87% of Cytori Therapeutics worth $703,000 at the end of the most recent reporting period. Hedge funds and other institutional investors own 10.01% of the company’s stock.
About Cytori Therapeutics
Cytori Therapeutics, Inc (Cytori) is a biotechnology company engaged in the development of treatments and devices for a range of disorders using cells as a key part of the therapy. The Company develops cellular therapeutics formulated and optimized for specific diseases and medical conditions and related products.
Receive News & Ratings for Cytori Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cytori Therapeutics Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.